Form 4 for RGEN REPLIGEN CORP
Accepted 2024-09-04 00:00:00 ET · period of report 2024-09-03 · accession 0000950170-24-103643 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-09-04 | 2024-09-03 | RGEN | Loeillot Olivier | CEO, Dir | A - Grant | $0.00 | +17.6K | 33.4K | +112% | $0 |
| D | 2024-09-04 | 2024-09-03 | RGEN | Loeillot Olivier | CEO, Dir | A - Grant | $0.00 | +16.3K | 16.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-03 | A | A | 17,631 | $0.00 | 33,417 | D | — | — | (F1) Mr. Loeillot was awarded 17,631 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-09-03 | A | A | 16,278 | $0.00 | 16,278 | D | $141.79 · — to 2034-09-03 | 16,278 Common Stock | (F2) One third of the stock options will vest and become exercisable annually on September 3, 2025, September 3, 2026, and September 3, 2027. |